Suitable groups for the hexavalent cervical cancer vaccine

The hexavalent cervical cancer vaccine is suitable for women aged 9-45, and it is especially recommended for those who are not infected with human papillomavirus and do not have cervical precancerous lesions. The vaccine can prevent HPV types 6, 11, 16, 18, 31, and 33 infections and reduce the risk of cervical cancer and genital warts. Contraindications such as pregnancy, acute infection, and severe immune deficiency must be excluded before vaccination.

1. Adolescent women

Females aged 9-14 years old are the priority group for vaccination. At this time, the immune response is strong and most of them have not been exposed to the HPV virus. The two-dose regimen induces durable antibody responses, and the World Health Organization recommends including this age group in national immunization programs. Parents need to complete the full course of vaccination before girls have sex for the first time, and the prevention effect can reach more than 90%.

2. Young adult women

Vaccination for women aged 15-26 can still achieve significant protective effects, but three doses are required. There may already be a single type of HPV infection at this stage, and the vaccine can still protect against other uninfected types. It is recommended to evaluate the necessity of vaccination during the first gynecological examination, especially for those with high-risk factors such as multiple sexual partners or smoking.

3. Middle-aged women

Vaccination for women aged 27-45 requires individualized evaluation. The vaccine is still 50-70% protective against uninfected types. The U.S. Food and Drug Administration approves it for use in this age group, but be aware that immune responses may weaken as you age. It is recommended that you discuss your past sexual history and cervical screening results with your doctor before making any decisions.

4. Special health conditions

People with low immune function, such as those infected with HIV, need to evaluate their CD4 cell count before vaccination, and may need to increase the dose. Antibody levels should be monitored after vaccination in patients with autoimmune diseases. Vaccination is not recommended during pregnancy, but it is safe for use by breastfeeding women. Regular cervical cancer screening is still required after vaccination.

5. Male group

Currently, the hexavalent vaccine is not approved for male vaccination in China, but international studies have shown that it can prevent anal cancer and genital warts. High-risk groups such as gay men and HIV-positive people can receive the nine-valent vaccine abroad. Vaccination of men can help block the chain of HPV transmission and achieve herd immunity effect.

You should observe for 30 minutes after vaccination to prevent allergic reactions. Minor reactions such as redness, swelling and pain at the injection site may occur. Keep the vaccination site clean and dry and avoid strenuous exercise for 24 hours. Even after completing the full course of vaccination, women over the age of 30 still need to undergo combined TCT and HPV screening every 3-5 years. Paying attention to safe sexual behavior every day, quitting smoking and limiting alcohol, and strengthening immunity can help improve the protective effect of vaccines. If pregnancy is discovered during vaccination, subsequent doses should be suspended. Postpartum catch-up vaccination will not affect the efficacy of the vaccine.